Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00452673
- Locations
- 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT00439270
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates Of Rockland, Nyack, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00438854
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT00436605
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Yale University, New Haven, Connecticut, United States
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT00429949
- Locations
- 🇺🇸
Washington Universtiy in St. Louis, St. Louis, Missouri, United States
Gemcitabine and Dasatinib in Advanced Solid Tumors
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00429234
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00423735
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 85
- Registration Number
- NCT00410813
- Locations
- 🇺🇸
Hurley Medical Center, Flint, Michigan, United States
🇺🇸University of Mississippi Cancer Clinic, Jackson, Mississippi, United States
🇺🇸St. James Healthcare Cancer Care, Butte, Montana, United States
Treatment of Adult Ph+ LAL With BMS-354825
- Conditions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2017-01-04
- Target Recruit Count
- 53
- Registration Number
- NCT00391989
- Locations
- 🇮🇹
Presidio Ospedaliero "C. e G.Mazzoni", Ascoli Piceno, Italy
🇮🇹Ist.Ematologia e Oncologia Medica L.e A. Seragnoli, Bologna, Italy
🇮🇹Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna, Ferrara, Italy
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00390793
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.